The highly effective anorexigen (ϩ)-fenfluramine (Redux) was widely prescribed for the treatment of obesity until it was associated with primary pulmonary hypertension (Abenhaim et al., 1996) and aortic valvular disease (Connolly et al., 1997). We have reported previously that the hepatic deethylated metabolite of (ϩ)-fenfluramine, (ϩ)-norfenfluramine, is vasoactive. (ϩ)-Norfenfluramine causes contraction in isolated rat aorta, renal artery, and mesenteric resistance artery and increases blood pressure through activation of 5-hydroxytryptamine (5-HT) 2A receptor (Ni et al., 2004a).Recently, we found that 5-HT and a functional 5-HTT are present in rat peripheral arteries (Ni et al., 2004b). 5-HT is a vasoconstrictor and causes contraction in many arteries and veins, especially conduit vessels via 5-HT 2A receptors (Martin, 1994). (ϩ)-Fenfluramine and (ϩ)-norfenfluramine are 5-HTT substrates and potent 5-HT releasers (Garattini, 1995;Rothman and Baumann, 2002). Because the anorexic effect of (ϩ)-fenfluramine was considered to be due at least in part to 5-HT release (Fishman, 1999), we hypothesized that (ϩ)-norfenfluramine-induced vasoconstriction is dependent on release of endogenous 5-HT via 5-HTT with consequent 5-HT-induced activation of 5-HT 2A receptor-mediating contraction.We studied our hypothesis by using two different strains of mice. Aorta from tryptophan hydroxylase (TPH) 1-deficient